TrialBMC cancer2016

The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.

Hyun-Ah Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.